Figure 4.

Mice bearing B16-F10 lung metastases show enhanced survival when treated with anti–CTLA-4 and F10/g vaccine. B16-F10 cells (5 × 10⁴ per mouse) were injected into the tail vein and 24 h later, treatment was started using control hamster IgG (10 mice, ○), anti–CTLA-4 antibody 9H10 (9 mice; •), irradiated F10/g (10⁶ subcutaneously) in combination with hamster IgG (10 mice; □) or 9H10 (13 mice; ▪) on days 1, 4, and 7, according to the dosing schedule used for subcutaneous tumors (see Fig. 1 legend). Mice were followed for survival, and in some subjects death due to extensive pulmonary metastasis was confirmed by harvesting lungs postmortem.